Les enjeux de la vaccination chez les patients atteints de cancer : focus sur les infections respiratoires (notice n° 2209667)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02479cam a2200337 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260412000344.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Loubet, Paul |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les enjeux de la vaccination chez les patients atteints de cancer : focus sur les infections respiratoires |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2026.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 33 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les patients atteints de cancers solides présentent une vulnérabilité accrue aux infections respiratoires, liée à l’immunodépression induite par les traitements, à l’âge, aux comorbidités et à l’exposition hospitalière répétée. Les virus grippaux, le virus respiratoire syncytial (VRS), le SARS-CoV-2 et le pneumocoque sont responsables d’une morbi-mortalité significative dans cette population, y compris chez les patients en rémission, avec des conséquences directes sur le pronostic et la continuité des traitements oncologiques. Cet article fait le point sur le fardeau représenté par ces infections respiratoires évitables par la vaccination et souligne l’importance d’une stratégie vaccinale renforcée, intégrée à la prise en charge globale des patients atteints de cancer. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Patients with solid cancers are more vulnerable to respiratory infections due to treatment-induced immunosuppression, age, comorbidities and repeated hospital exposure. Influenza viruses, respiratory syncytial virus (RSV), SARS-CoV-2 and pneumococcus are responsible for significant morbidity and mortality in this population, including patients in remission, with direct consequences for the prognosis and continuity of oncological treatments. This article reviews the burden of these respiratory infections, which can be prevented by vaccination, and highlights the importance of a reinforced vaccination strategy as part of the overall management of cancer patients. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | grippe |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pneumocoque |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | SARS-CoV-2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vaccins |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | virus respiratoires |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | VRS |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancer |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | influenza |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pneumococcus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | respiratory viruses |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | RSV |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | SARS-CoV-2 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | vaccines |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 12 | N° Supp 1 | 2026-04-08 | p. 4-7 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2026-HS1-page-4?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2026-HS1-page-4?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux